• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Probiodrug AG - Articles and news items

Probiodrug

Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences

Industry news / 17 November 2014 / Probiodrug

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences…

Probiodrug

Probiodrug raises €22.5 million in successful Initial Public Offering and listing on Euronext Amsterdam

Industry news / 24 October 2014 / Probiodrug

Probiodrug AG announces the successful completion of its Initial Public Offering, which was launched on 10 October 2014 (the “IPO” or the “Offering”)…

Probiodrug

Probiodrug launches its Initial Public Offering and listing on Euronext Amsterdam

Industry news / 13 October 2014 / Probiodrug AG

Probiodrug AG announces the launch of its Initial Public Offering and listing on Euronext Amsterdam…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +